Obesity is a major health problem in the world, and is increasing both in prevalence and severity. Since it poses a major risk for various serious chronic diseases, it is very important to prevent and treat obesity.
The main prescription products currently approved for obesity are sibutramine (Abbott’s Meridia®) and orlistat (Roche’s Xenical®). Sibutramine inhibits the reuptake of noradrenaline and serotonin, controlling appetite and therefore decreasing food intake. Sibutramine, however, has well known side effects associated with sympathomimetic properties, affecting heart rate and blood pressure.
In contrast to sibutramine, orlistat acts locally. Orlistat is a gastric and pancreatic lipase inhibitor that prevents fat hydrolysis, thus reduces dietary fat absorption by approximately 30%. However, undigested fat along the gastrointestinal track cause side effects, which is not only uncomfortable but also socially unacceptable. Therefore, a new type of anti-obesity treatment needs to be actively sought because the current pharmaceutical drugs are not ideal for the treatment of obesity.
A probiotic strain was mutagenized to isolate JBD 301 series that could inhibit fat absorption, which result in reduction of energy intake and thus weight reduction.
JINIS JBD-301, a novel microbe strain (Patent-pending), inhibits absorption of fat in the gastrointestinal track, reducing calorie intake.
JBD-301 successfully reduced visceral fat accumulation and body weight while it does not show serious side effects reported with current drug. Administration of JBD-301 reduced visceral fat accumulation and body weight gain about 20% compared to the control as well as improving blood biochemical profiles relating to metabolic syndrome.
This implies JBD-301 can be developed as both SAFE and EFFECTIVE drug for the treatment of obesity as well as other associated health hazards, including cardiovascular disease and diabetes.